Rossi et al identified molecular features associated with a durable response to chemotherapy by a patient with chronic lymphocytic leukemia (CLL). The authors are from multiple institutions in Italy.
Patient selection: chronic lymphocytic leukemia treated with chemotherapy (Rossi et al reported for fludarabine-cyclophosphamide-rituximab=FCR; Gentile et al reported for bundamustine-rituximab).
Parameters:
(1) mutation status of IGHV
(2) del (17p) by FISH
(3) del(11q) by FISH
Findings
Risk Group
2-Year PFS
IGHV mutated without del(11q) or del(17p)
low
77%
IGHV unmutated OR del(11q)
intermediate
65%
del(17p)
high
26%
To read more or access our algorithms and calculators, please log in or register.
